Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per specialist: Heung Tae Kim, M.D
Woman and Man Max 99 years
Heung Tae Kim, M.D
Update Il y a 5 ans
Paclitaxel and Capecitabine in Patients With Metastatic/Recurrence Esophageal Cancer
Capecitabine is an orally administered fluoropyrimidine that is converted by 5-FU by thymidine phosphorylase (TP), preferentially in tumor tissues and has demonstrated activity as single a...
Country
Korea, Republic of
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Heung Tae Kim, M.D
Update Il y a 4 ans
A Study of TS-1 Plus Irinotecan and Cisplatin (IP) for Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)
The irinotecan and cisplatin combination showed significant anti-tumor activity. In the first-line setting, the investigators showed that this regimen had significant anti-tumor activity i...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Heung Tae Kim, M.D
Update Il y a 4 ans
Pre-operative Chemotherapy Versus Concurrent Chemoradiotherapy in N2 Positive IIIA Non Small Cell Lung Cancer (NSCLC)
It is suggested that a bimodal or trimodal approach combining neoadjuvant chemotherapy with or without radiotherapy followed by surgery provides a potentially superior method of enhancing ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Heung Tae Kim, M.D
Update Il y a 4 ans
Gemcitabine Plus Oxaliplatin in Advanced Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)
Oxaliplatin is a diaminocyclohexane platinum compound, with a mechanism of action similar to that of cisplatin. Oxaliplatin has a more manageable toxicity profile than cisplatin, with no r...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Heung Tae Kim, M.D
Update Il y a 4 ans
Weekly Paclitaxel Plus Gemcitabine as Second-line in Small Cell Lung Cancer
As a single agent, paclitaxel has a response rate of 33% and 25-29% in SCLC patients with sensitive relapse and with resistant relapse, respectively. As a single agent, gemcitabine also ha...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Heung Tae Kim, M.D., Ph.D
Update Il y a 4 ans
Study to Assess of Belotecan or Topotecan on Daily Schedule in Relapsed Small Cell Lung Cancer (SCLC) Patients
The purpose of this study is to evaluate the efficacy and safety of Belotecan administered 5 days every 3 weeks in comparison to Topotecan in Patients with relapsed small cell lung cancer.
Country
None
organs
None
Specialty
None
Opened trial
More information